antibody drug conjugate sc 004

Drug Overview

The anti-CLDN6/9 antibody-drug conjugate SC-004 (often just called SC-004) is an experimental cancer medication. It belongs to a highly advanced group of medicines known as Targeted Therapy. Often called a “Smart Drug,” this medication is designed to seek out and destroy specific cancer cells while trying to spare the healthy cells in the rest of your body.

• Generic Name: anti-CLDN6/9 antibody-drug conjugate SC-004 (SC-004)
• US Brand Names: None (Investigational drug)
• Drug Class: Antibody-Drug Conjugate (ADC) / Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA Approved. This medication was developed specifically for clinical trials and is not available for standard public use.
  
  Get facts on the antibody drug conjugate sc 004. We deliver precise diagnostics and world-class oncology care at our advanced medical hospital.

What Is It and How Does It Work? (Mechanism of Action)

To understand how SC-004 works, you can picture it as a microscopic delivery truck carrying a powerful weapon. As an Antibody-Drug Conjugate (ADC), it is made of an antibody (the tracker) linked to a powerful chemotherapy toxin (the payload).

Here is how the “Smart Drug” works at the molecular level:

1. Finding the Target (CLDN6/9): Ovarian and endometrial cancer cells often have high amounts of specific proteins on their surface called Claudin-6 (CLDN6) and Claudin-9 (CLDN9). Healthy adult cells rarely have these proteins.
2. Locking On: The antibody part of SC-004 floats through the bloodstream until it finds these Claudin proteins. It then locks onto the cancer cell like a key in a lock.
3. Getting Inside: Once locked on, the cancer cell mistakenly absorbs the drug, pulling it inside.
4. Releasing the Weapon: Inside the cell, the drug breaks apart. This releases the hidden payload a very strong chemotherapy toxin called a PBD dimer (pyrrolobenzodiazepine).
5. Destroying the DNA: The PBD toxin travels to the center of the cancer cell and glues the strands of the cell’s DNA together (DNA cross-linking). Because the cancer cell can no longer read or copy its DNA, it cannot divide, and it quickly dies.

FDA-Approved Clinical Indications

Because SC-004 is an experimental drug, it does not have any FDA-approved uses for the general public. However, researchers have tested it in clinical trials for the following conditions:

Investigational Oncological Uses

• Platinum-Resistant Epithelial Ovarian Cancer
• Advanced Endometrial Carcinoma
• Fallopian Tube Carcinoma
• Primary Peritoneal Carcinoma

Investigational Non-Oncological Uses

• None. This drug is uniquely designed to fight cancer.

Dosage and Administration Protocols

Note: Because SC-004 is an experimental medication, there is no standard prescription dosage. The information below reflects the protocols used during its Phase 1 clinical trial testing.

Clinical Efficacy and Research Results

When looking at clinical study data, SC-004 was primarily tested in a Phase 1 clinical trial (which wrapped up around 2020-2021) for women with advanced ovarian and endometrial cancers. The main goal of a Phase 1 trial is to see if a drug is safe and to find the right dose.

• Disease Control: Out of the patients evaluated, about 73% achieved “stable disease.” This means the targeted therapy successfully stopped the tumors from growing for a period of time.
• Tumor Shrinkage: About 5% of patients had a “partial response,” meaning their tumors noticeably shrank.
• Research Outcome: While the drug proved it could successfully hit the Claudin targets, it caused too many side effects at the doses needed to kill the cancer. Because of this low tolerability and insufficient overall benefit, the development of this specific drug was halted, and it did not advance to Phase 3 trials.

Safety Profile and Side Effects

The PBD toxin used inside SC-004 is extremely strong. While the drug tries to only target cancer, some of the toxin can affect healthy tissues, leading to specific side effects.

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or exhausted (affecting about 38% of patients).
• Edema: Swelling in the hands, arms, feet, or legs (33%).
• Gastrointestinal Issues: Nausea, vomiting, and diarrhea (around 20-33%).
• Pleural Effusion: Fluid building up in the space around the lungs, making it harder to breathe (25%).

Serious Adverse Events

• Pericardial Effusion: In some cases, dangerous fluid can build up around the heart, which is a severe medical emergency.
• Severe Fluid Retention: Massive fluid buildup in the chest and abdomen that requires immediate hospital care.

Black Box Warning

Because SC-004 is not an FDA-approved drug, it does not carry an official Black Box Warning. However, doctors treat all drugs carrying PBD toxins with extreme caution, acting as if they have strict warnings for severe fluid retention (effusions) and life-threatening toxicity.

Management Strategies

If a patient develops swelling or fluid around the lungs, doctors will prescribe strong diuretics (water pills) to help flush the extra fluid out through the urine. If fluid around the lungs causes shortness of breath, a doctor can safely perform a routine procedure (thoracentesis) to drain the fluid with a small needle, helping the patient breathe comfortably again.

Research Areas: Connection to Embryonic and Stem Cell Pathways

One of the most interesting things about SC-004 is its target: Claudin-6 (CLDN6). CLDN6 is known as an “embryonic antigen.” This means it is heavily used by stem cells and growing tissues when a baby is developing in the womb, but it completely turns off once we become healthy adults. However, ovarian cancer cells often mutate and “turn back the clock,” reactivating these embryonic pathways to help the tumor grow rapidly. By studying drugs like SC-004, researchers in cancer biology and regenerative medicine are learning how to attack these hidden stem-cell-like proteins to stop cancer from regenerating.

Patient Management and Practical Recommendations

For patients taking part in clinical trials for drugs that carry a high risk of fluid retention, strict rules are followed to keep them safe.

Pre-Treatment Tests

• Imaging: Chest X-rays and echocardiograms (ultrasounds of the heart) to make sure there is no hidden fluid before starting treatment.
• Blood Work: Comprehensive metabolic panels to check kidney and liver health, plus complete blood counts (CBC).

Precautions During Treatment

Patients with a history of heart failure or serious breathing problems are closely watched, as any extra fluid buildup could be very dangerous for them.

Do’s and Don’ts

• DO weigh yourself at the same time every single morning. If you gain 3 or more pounds in just a few days, call your doctor—this is an early sign of fluid buildup.
• DO report any new shortness of breath, heavy chest feelings, or swollen ankles to your care team right away.
• DO eat small, frequent meals if you feel nauseous.
• DON’T ignore sudden fatigue or dizziness; always let your nurses know how you feel.
• DON’T start any new medicines, herbal supplements, or vitamins without checking with your cancer doctor first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. The anti-CLDN6/9 antibody-drug conjugate SC-004 is an investigational compound and is not approved by the FDA, EMA, or other global regulatory agencies for the treatment of any disease. Patients should always consult with a qualified, licensed healthcare professional or oncologist regarding treatment options, clinical trials, and medication safety. Do not disregard professional medical advice or delay seeking it because of information provided on this website.